In lung pathologies such as asthma [8], pulmonary fibrosis [9] and pulmonary hypertension [10, 11], genetic deletion of Sphk1 or inhibition of SphK1 activity with small molecule inhibitors conferred significant protection from airway/lung inflammation and injury. Here, SPHK1 is linked to pulmonary arterial hypertension.